

MAR. 7. 2006 8:37AM

CHOATE HALL &amp; STEWART 6172484000

NO. 420 P. 1

CHOATE

CHOATE HALL &amp; STEWART LLP

RECEIVED  
CENTRAL FAX CENTER

MAR 07 2006


**Fax****CONFIDENTIAL**

<b>Recipient</b>	<b>Company</b>	<b>Fax</b>	<b>Phone</b>
Art Unit 1653	USPTO	(571) 273-8300	
<b>From</b>	Nadège M. Lagneau, Ph.D.	<b>Number of Pages</b>	9 (including this page)
<b>Date</b>	March 7, 2006	<b>Client Number</b>	2004117-0008
<b>Phone</b>	(617) 248-5150	<b>Operator</b>	<b>Time Sent</b>
<b>Comments</b>	Applicant: Carr, et al. Serial No.: 10/828,623 Filed: April 21, 2004 For: NOVEL CHIMERIC ANALGESIC PEPTIDES	Examiner: Group Art Unit:	TBA 1653

Please find enclosed for filing in the above-identified patent application:

1. Transmittal (1 page);
2. PTO 1449 (1 page);
2. Supplemental IDS Statement (6 pages); and
3. Facsimile cover sheet (1 page).

Respectfully submitted,



Nadège M. Lagneau, Ph.D.  
Reg. No.: 51,908

Return by      Inter-office Mail      Hold for pick-up

This Message is transmitted to you by the law firm of Choate, Hall & Stewart LLP. The substance of this message, along with any attachments, may be confidential and legally privileged. If you are not the designated recipient of this message, please destroy it and notify the sender of the error by return e-mail or by calling 1-800-620-2427.

Under regulations of the Treasury Department, we are required to include the following statement in this message: Any advice contained herein (or in any attachment hereto) regarding federal tax matters was not intended or written by the sender to be used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

For more information about Choate, Hall & Stewart LLP, please visit us at [www.choate.com](http://www.choate.com)  
Two International Place | Boston MA 02110 | t 617-248-5000 | f 617-248-4000 | [choate.com](mailto:choate.com)

4051971v1

**ATTORNEY DOCKET NUMBER: 2004117-0008 (NEMC 197-DIV)**


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Carr, et al.  
 Serial No.: 10/828,623  
 Filed: April 21, 2004  
 For: NOVEL CHIMERIC ANALGESIC PEPTIDES

Examiner: TBA  
 Group Art Unit: 1653

Mail Stop: Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

<b>Certificate of Facsimile Transmission</b> Pursuant to 1096 OG 30-31 I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office (571) 273-8300 on the date indicated below.	
March 7, 2006	
Date	Signature
Mary B. Wilson	
Typed or Printed Name of person signing certificate	


**TRANSMITTAL**

Please find enclosed for filing in the above-identified patent application:

1. PTO 1449 (1 page);
2. Supplemental IDS Statement (6 pages); and
3. Facsimile cover sheet (1 page).

Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,

  
 Nadège M. Lagneau, Ph.D.  
 Reg. No.: 51,908

Dated: March 7, 2006

PATENT GROUP  
 CHOATE, HALL & STEWART LLP  
 Two International Place  
 Boston, MA 02110  
 Telephone: (617) 248-5000  
 Facsimile: (617) 248-4000

U.S.S.N. 10/828,623  
 4051970v1

Page 1 of 1

Atty Docket No.: 2004117-0008  
 Client Ref.: NEMC 197 DIV

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2004117-0008 (NEMC 197-DIV)	In re Application No. 10/828,623
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		Applicant: Carr <i>et al.</i>	
(Use several sheets if necessary)		Filing Date: April 21, 2004	Group: 1653

**U. S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	✓ 6,063,758	Lappi <i>et al.</i>	05/16/00		
	✓ 6,310,072	Smith <i>et al.</i>	10/30/01		

**U. S. PATENT APPLICATIONS**

	Document No.	Applicant	Filing Date		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Document No.	Country	Publication Date	Translation	
				Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	✓ Cavagnero <i>et al.</i> , <i>Life Sci.</i> , 49(7):498-503, 1991.
	✓ Watson <i>et al.</i> , <i>Eur. J. Pharmacol.</i> , 87(1):77-84, 1983.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

- ✓ Cited by the Examiner in parent case USSN 09/428,692 (US Patent No.: 6,759,520).


RECEIVED  
CENTRAL FAX CENTER  
MAR 7 2006

ATTORNEY DOCKET NUMBER: 2004117-0008 (NEMC 197-DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Carr, et al. Examiner: TBA  
Serial No.: 10/828,623 Group Art Unit: 1653  
Filed: April 21, 2004  
For: NOVEL CHIMERIC ANALGESIC PEPTIDES

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

<b>Certificate of Facsimile Transmission</b> <b>Pursuant to 1096 OG 30-31</b>	
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office (571) 273-8300 on the date indicated below.	
<u>March 7, 2006</u> Date	 Signature <u>Mary B. Wilson</u>
Typed or Printed Name of person signing certificate	

Sir:

**STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

An *original* Information Disclosure Statement; or  
 A *supplemental* Information Disclosure Statement.

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

Pursuant to 37 CFR § 1.97(b); no fee or certification is required:

Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);

Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;

Before the mailing of a first Office action on the merits; or

Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:

Certifies that *either*:

each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

[ ] Includes herewith the fee set forth in § 1.17(p).

[ ] Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

[ ] Certifies that *either*:

[ ] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

[ ] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

[X] A copy of each cited reference not indicated with a check mark (✓) is included;

[X] Copies of references indicated with a check mark (✓) on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously cited by the Examiner in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status
09/428,692	October 28, 1999	Granted
(Patent No.: 6,759,520)		

[ ] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

[ ] Does not contain non-English language citations;

[ ] Does contain non-English language citations, of which the following is a concise explanation:

[ ] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:


1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and

3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

  
Nadège M. Lagneau, Ph.D.  
Reg. No. 51,908

Dated: March 7, 2006

PATENT DEPARTMENT  
CHOATE, HALL & STEWART LLP  
Two International Place  
Boston, Massachusetts 02110  
Tel: (617) 248-5000  
Fax: (617) 248-4000